Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (2016) Vol. 62, pp. 138-145
Open Access | Times Cited: 285

Showing 1-25 of 285 citing articles:

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 3, pp. e143-e152
Open Access | Times Cited: 1992
Artificial intelligence in cancer imaging: Clinical challenges and applications
Wenya Linda Bi, Ahmed Hosny, Matthew B. Schabath, et al.
CA A Cancer Journal for Clinicians (2019) Vol. 69, Iss. 2, pp. 127-157
Open Access | Times Cited: 1394
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al.
European Urology (2020) Vol. 79, Iss. 2, pp. 263-282
Closed Access | Times Cited: 902
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
Matthias Pinter, Rakesh K. Jain, Dan G. Duda
JAMA Oncology (2020) Vol. 7, Iss. 1, pp. 113-113
Open Access | Times Cited: 259
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Laura Fugazzola, Rossella Elisei, Dagmar Führer, et al.
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 227-245
Open Access | Times Cited: 239
<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>
Huan Wang, Xiaoyun Mao
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 2423-2433
Open Access | Times Cited: 156
Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
Annika Fendler, Daniel Bauer, Jonas Busch, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 148
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
Elena Élez, Javier Ros, J. Fernández, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2162-2170
Open Access | Times Cited: 83
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy
Marwan Fakih, Jaideep Sandhu, Dean Lim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 627-627
Open Access | Times Cited: 55
Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells
Tianyu Cao, Wenyao Zhang, Qi Wang, et al.
Cell (2024) Vol. 187, Iss. 9, pp. 2288-2304.e27
Closed Access | Times Cited: 49
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
Fabian Jost‐Brinkmann, Münevver Demir, Alexander Wree, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1313-1325
Open Access | Times Cited: 44
Review on Alzheimer Disease Detection Methods: Automatic Pipelines and Machine Learning Techniques
Amar Shukla, Rajeev Tiwari, Shamik Tiwari
Sci (2023) Vol. 5, Iss. 1, pp. 13-13
Open Access | Times Cited: 43
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
Jianzhen Lin, Xu Yang, Junyu Long, et al.
HepatoBiliary Surgery and Nutrition (2020) Vol. 9, Iss. 4, pp. 414-424
Open Access | Times Cited: 131
RECIST — learning from the past to build the future
Saskia Litière, Sandra Collette, Elisabeth G.E. de Vries, et al.
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 3, pp. 187-192
Closed Access | Times Cited: 112
Alterations in DNA Damage Repair Genes in Primary Liver Cancer
Jianzhen Lin, Junping Shi, Honglin Guo, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 15, pp. 4701-4711
Open Access | Times Cited: 96
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
Nandita M. deSouza, Eric Achten, Ángel Alberich‐Bayarri, et al.
Insights into Imaging (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 80
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain
Susanne Grünewald, Lillian R. Klug, Thomas Mühlenberg, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 108-125
Open Access | Times Cited: 72
Structured reporting in radiology: a systematic review to explore its potential
J. Martijn Nobel, Koos van Geel, Simon G. F. Robben
European Radiology (2021) Vol. 32, Iss. 4, pp. 2837-2854
Open Access | Times Cited: 63
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
Yin Liu, Xiuzhi Zhu, Yi Xiao, et al.
Cell Research (2023) Vol. 33, Iss. 5, pp. 389-402
Open Access | Times Cited: 37
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
Rahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 11, pp. 1266-1276
Open Access | Times Cited: 34
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
Tim Flaadt, Ruth Ladenstein, Martin Ebinger, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 17, pp. 3135-3148
Open Access | Times Cited: 28
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
Odrade Gondry, Catarina Xavier, Laurens Raes, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 9, pp. 1378-1384
Open Access | Times Cited: 26
A call to action to advance patient‐focused and decentralized clinical trials
R. Donald Harvey, Therica M. Miller, Patricia A. Hurley, et al.
Cancer (2024) Vol. 130, Iss. 8, pp. 1193-1203
Open Access | Times Cited: 15
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mina Kim, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 345-359
Open Access | Times Cited: 13
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
Chengpei Zhu, Yunchao Wang, Ruijuan Zhu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top